Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing

Aligos Therapeutics, Inc.

Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.
Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.
Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.
ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.
James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported the fourth quarter and full year 2025 results: net income Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share o, EPS $(1.91).

Period: the fourth quarter and full year 2025
Net income: Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share o
EPS: $(1.91)
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2025 was $19.9 million or basic and diluted net loss per common share of $(1.91), compared to net loss of $82.2 million or basic and diluted net loss per common share of $(13.08) for the three months ended December 31, 2024.

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-26-001340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.